Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

Research Excellence

Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free acids and bound-to-phospholipid esters, derived from krill oil.

Read more

Definitive Agreement to Acquire Grace Therapeutics, Inc.

Acasti recently announced it has entered into a definitive agreement to acquire Grace Therapeutics, Inc., a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases

Read more


Acasti Pharma advanced an omega-3 therapeutic, CaPre®, designed for the treatment of hypertriglyceridemia through two Phase 3 clinical trials: the TRILOGY trials. In TRILOGY 1, CaPre® achieved a 30.5% reduction in triglyceride levels at 12 weeks and 36.7% reduction in triglyceride levels at 26 weeks, as well as 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks. Despite positive results in the CaPre arm, the TRILOGY 1 study did not reach statistical significance. In TRILOGY 2, CaPre achieved 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint.

Our Science

Since 2008, Acasti Pharma’s scientists have focused on the research and development of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of cardiometabolic diseases.

The Team

Our passionate executives and scientists bring decades of experience developing and commercializing novel therapeutics.